Impact of Personalized Dosing of Faricimab on Treatment Outcomes in nAMD

Video

Dr Varun Chaudhary discusses the impact of personalized treat-and-extend-based dosing on visual and anatomic outcomes of faricimab in the TENAYA and LUCERNE clinical trials in neovascular AMD.

Newsletter

Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.

Subscribe Now!
Recent Videos
Ursula Schmidt-Erfurth, MD, Professor of Ophthalmology at the Medical University of Vienna, Austria, discusses her keynote EURETINA Lecture, artificial intelligence and age-related macular degeneration.
At ARVO 2025, Christine Kay, MD, shares interim results from the PRISM trial population extension cohort
Related Content
Belite Bio concludes phase 3 DRAGON study for Stargardt disease

Belite Bio concludes phase 3 DRAGON study for Stargardt disease

Kassi Filkins
September 18th 2025
Article
Optain Health secures $26 million Series A funding

Optain Health secures $26 million Series A funding

Kassi Filkins
September 18th 2025
Article
New study examines soft drusen regression without atrophy and drusen ooze

New study examines soft drusen regression without atrophy and drusen ooze

Lynda Charters
September 18th 2025
Article
University of Houston researchers receive $3.6 million to examine retinal diseases

University of Houston researchers receive $3.6 million to examine retinal diseases

Jordana Joy
September 18th 2025
Article
Study links AMD to higher cardiovascular disease mortality in high-risk patients

Study links AMD to higher cardiovascular disease mortality in high-risk patients

Lynda Charters
September 18th 2025
Article
Alcon completes acquisition of LumiThera

Alcon completes acquisition of LumiThera

Martin David Harp
September 18th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.